Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 21 September 2010
Vol. 3, Issue 140, p. ra67
[DOI: 10.1126/scisignal.2001083]

RESEARCH ARTICLES

Editor's Summary

Rationally Designing Combination Therapy
Drug resistance is a problem in cancer treatment, making combination therapies common. However, all too often, resistance also develops to empirically developed combination therapies, or those combinations are generally cytotoxic and not selective for the cancer cells. Astsaturov et al. developed a library of candidate genes centered on the epidermal growth factor receptor (EGFR) and targeted these genes with silencing RNAs to identify candidate proteins that could be inhibited to reduce cancer cell viability in the presence of EGFR inhibitors. Cotreatment with EGFR inhibitors and clinically available drugs that inhibit the candidate proteins reduced tumor size in xenografts and cell viability of multiple cancer cell lines. These results suggest that this network-centered approach may be fruitful for development of rationally designed combination therapies.

Citation: I. Astsaturov, V. Ratushny, A. Sukhanova, M. B. Einarson, T. Bagnyukova, Y. Zhou, K. Devarajan, J. S. Silverman, N. Tikhmyanova, N. Skobeleva, A. Pecherskaya, R. E. Nasto, C. Sharma, S. A. Jablonski, I. G. Serebriiskii, L. M. Weiner, E. A. Golemis, Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies. Sci. Signal. 3, ra67 (2010).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
J. Li, K. Bennett, A. Stukalov, B. Fang, G. Zhang, T. Yoshida, I. Okamoto, J.-Y. Kim, L. Song, Y. Bai, et al. (2014)
Mol Syst Biol 9, 705
   Abstract »    Full Text »    PDF »
Molecular Pathways: Sterols and Receptor Signaling in Cancer.
L. Gabitova, A. Gorin, and I. Astsaturov (2014)
Clin. Cancer Res. 20, 28-34
   Abstract »    Full Text »    PDF »
Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer.
H. Liu, F. Xiao, I. G. Serebriiskii, S. W. O'Brien, M. A. Maglaty, I. Astsaturov, S. Litwin, L. P. Martin, D. A. Proia, E. A. Golemis, et al. (2013)
Clin. Cancer Res. 19, 5053-5067
   Abstract »    Full Text »    PDF »
KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer.
B. Dai, S.-Y. Yoo, G. Bartholomeusz, R. A. Graham, M. Majidi, S. Yan, J. Meng, L. Ji, K. Coombes, J. D. Minna, et al. (2013)
Cancer Res. 73, 5532-5543
   Abstract »    Full Text »    PDF »
Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.
T. Seeger-Nukpezah, D. A. Proia, B. L. Egleston, A. S. Nikonova, T. Kent, K. Q. Cai, H. H. Hensley, W. Ying, D. Chimmanamada, I. G. Serebriiskii, et al. (2013)
PNAS 110, 12786-12791
   Abstract »    Full Text »    PDF »
Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation.
A. Sukhanova, A. Gorin, I. G. Serebriiskii, L. Gabitova, H. Zheng, D. Restifo, B. L. Egleston, D. Cunningham, T. Bagnyukova, H. Liu, et al. (2013)
Cancer Discovery 3, 96-111
   Abstract »    Full Text »    PDF »
Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition.
M. Casas-Selves, J. Kim, Z. Zhang, B. A. Helfrich, D. Gao, C. C. Porter, H. A. Scarborough, P. A. Bunn Jr., D. C. Chan, A. C. Tan, et al. (2012)
Cancer Res. 72, 4154-4164
   Abstract »    Full Text »    PDF »
Computational Approaches for Analyzing Information Flow in Biological Networks.
B. Kholodenko, M. B. Yaffe, and W. Kolch (2012)
Science Signaling 5, re1
   Abstract »    Full Text »    PDF »
Delineation of key regulatory elements identifies points of vulnerability in the mitogen-activated signaling network.
N. Jailkhani, S. Ravichandran, S. R. Hegde, Z. Siddiqui, S. C. Mande, and K. V. S. Rao (2011)
Genome Res. 21, 2067-2081
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 4 January 2011.
M. B. Yaffe and A. M. VanHook (2011)
Science Signaling 4, pc1
   Abstract »    Full Text »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882